缺血性卒中或短暂性脑缺血发作后阿司匹林联合氯吡格雷的最佳疗程
短期A+C显著降低复发性缺血性卒中和大血管不良事件风险,且不增加大出血风险;长期A+C无获益且增加大出血和全因死亡风险。
要点
- 短期(≤1个月)A+C较阿司匹林单药显著降低复发性缺血性卒中风险(RR 0.53)。
- 中期(≤3个月)A+C仍降低复发性卒中风险(RR 0.72),但大出血风险增加(RR 2.58)。
- 长期(>3个月)A+C无获益,且增加大出血(RR 1.87)和全因死亡(RR 1.45)风险。
核心结论
- 短期A+C在急性缺血性卒中或短暂性脑缺血发作患者中较阿司匹林单药更有效且安全性相当。
- 长期A+C无获益且增加大出血和全因死亡风险。
研究设计与样本
- 检索MEDLINE、EMBASE和Cochrane Central Register of Controlled Trials(CENTRAL)至2018年6月。
主要发现
- 短期A+C显著降低复发性缺血性卒中风险(RR 0.53;95%CI 0.37-0.78)。
- 中期A+C显著降低复发性缺血性卒中风险(RR 0.72;95%CI 0.58-0.90)。
- 短期A+C显著降低主要不良心血管事件风险(RR 0.68;95%CI 0.60-0.78)。
- 中期A+C显著降低主要不良心血管事件风险(RR 0.76;95%CI 0.61-0.94)。
- 长期A+C对复发性缺血性卒中(RR 0.81;95%CI 0.63-1.04)和主要不良心血管事件(RR 0.87;95%CI 0.71-1.07)无显著获益。
关键数值与推荐
- 短期A+C大出血风险RR 1.82(95%CI 0.91-3.62)。
- 中期A+C大出血风险RR 2.58(95%CI 1.19-5.60)。
- 长期A+C大出血风险RR 1.87(95%CI 1.36-2.56)。
- 长期A+C全因死亡风险RR 1.45(95%CI 1.10-1.93)。
临床怎么用
- 急性缺血性卒中或短暂性脑缺血发作患者可考虑短期(≤1个月)A+C治疗以降低复发风险。
- 避免长期(>3个月)A+C治疗,因其无获益且增加出血和死亡风险。
局限性
- 研究基于随机对照试验的荟萃分析,结果受各试验异质性影响。
- 短期、中期和长期的定义基于月份分层,可能存在重叠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy compared with aspirin monotherapy in patients presenting with acute ischemic stroke (IS) or transient ischemic attack remains uncertain. We conducted this study to determine the optimal period of efficacy and safety of A+C compared with aspirin monotherapy. Methods- Ten randomized controlled trials (15 434 patients) were selected using MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) (inception June 2018) comparing A+C with aspirin monotherapy in patients with transient ischemic attack or IS. The primary efficacy outcome was recurrent IS, and the primary safety outcome was major bleeding. The secondary outcomes were major adverse cardiovascular events (composite of stroke, myocardial infarction, and cardiovascular mortality) and all-cause mortality. We stratified analysis based on the short- (≤1 month), intermediate- (≤3 month), and long-term (>3 month) A+C therapy. Effects were estimated as relative risk (RR) with 95% CI. Results- A+C significantly reduced the risk of recurrent IS at short-term (RR, 0.53; 95% CI, 0.37-0.78) and intermediate-term (RR, 0.72; 95% CI, 0.58-0.90) durations. Similarly, major adverse cardiovascular event was significantly reduced by short-term (RR, 0.68; 95% CI, 0.60-0.78) and intermediate-term (RR, 0.76; 95% CI, 0.61-0.94) A+C therapy. However, long-term A+C did not yield beneficial effect in terms of recurrent IS (RR, 0.81; 95% CI, 0.63-1.04) and major adverse cardiovascular events (RR, 0.87; 95% CI, 0.71-1.07). Intermediate-term (RR, 2.58; 95% CI, 1.19-5.60) and long-term (RR, 1.87; 95% CI, 1.36-2.56) A+C regimens significantly increased the risk of major bleeding as opposed to short-term A+C (RR, 1.82; 95% CI, 0.91-3.62). Excessive all-cause mortality was limited to long-term A+C (RR, 1.45; 95% CI, 1.10-1.93). Conclusions- Short-term A+C is more effective and equally safe in comparison to aspirin alone in patients with acute IS or transient ischemic attack.
引用
- Rahman H, Khan SU, Nasir F, et al. Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. Stroke. 2019. PMID: 30852971. doi:10.1161/STROKEAHA.118.023978
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。